SCHEMBL6348987

SCHEMBL6348987

Cc1cc(NC(=O)C(C)(C)C(=O)Nc2cc(C)[nH]n2)n[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 2/20 0.55
CDK2 P24941 2/20 0.55
CCNA1 P78396 2/20 0.55
NPC1 O15118 8/20 0.49
RAB9A P51151 8/20 0.49
ATM Q13315 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
RET P07949 4/20 0.43
LCK P06239 1/20 0.43
SRC P12931 1/20 0.43
DAO P14920 1/20 0.43
HCAR2 Q8TDS4 1/20 0.43
SYK P43405 1/20 0.42
ALPL P05186 1/20 0.42
ALPG P10696 1/20 0.42
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2873998 0.84 CCNA2 (0.54) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL6349668 0.81 CCNA2 (0.62) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL6341559 0.81 CCNA2 (0.62) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL3498417 0.79 CCNA2 (0.60) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL29972030 0.78 CCNA2 (0.58) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL6341557 0.75 CCNA2 (0.85) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL19538989 0.75 CCNA2 (0.55) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL3500966 0.72 ALPL (0.57) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL28413195 0.72 CDK2 (0.62) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL21687025 0.72 CCNA2 (0.51) CCNA2CDK2CCNA1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239808-A1 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239808-A1 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur PRNP, APP, MAPT CCNA2 2618/4885CDK2 2181/4885CCNA1 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.